Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where L B Reller is active.

Publication


Featured researches published by L B Reller.


American Journal of Transplantation | 2008

Survival After Lung Transplantation of Cystic Fibrosis Patients Infected with Burkholderia cepacia Complex

Barbara D. Alexander; E. W. Petzold; L B Reller; Scott M. Palmer; R.D. Davis; Christopher W. Woods; John J. LiPuma

Within the Burkholderia cepacia complex (Bcc), B. cenocepacia portends increased mortality compared with other species. We investigated the impact of Bcc infection on mortality and re-infection following lung transplant (LT). Species designation for isolates from Bcc-infected patients was determined using 16S rDNA and recA gene analyses. Of 75 cystic fibrosis patients undergoing LT from September 1992 to August 2002, 59 had no Bcc and 16 had Bcc (including 7 B. cenocepacia) isolated in the year before LT. Of the latter, 87.5% had Bcc recovered after transplantation, and all retained their pretransplant strains. Survival was 97%, 92%, 76% and 63% for noninfected patients; 89%, 89%, 67% and 56% for patients infected with Bcc species other than B. cenocepacia; and 71%, 29%, 29% and 29% for patients with B. cenocepacia (p = 0.014) at 1 month, 1 year, 3 years and 5 years, respectively. Patients infected with B. cenocepacia before transplant were six times more likely to die within 1 year of transplant than those infected with other Bcc species (p = 0.04) and eight times than noninfected patients (p < 0.00005). Following LT, infection with Bcc species other than B. cenocepacia does not significantly impact 5-year survival whereas infection with B. cenocepacia pretransplant is associated with decreased survival.


Journal of Clinical Microbiology | 2013

Controlled Multicenter Evaluation of a Bacteriophage-Based Method for Rapid Detection of Staphylococcus aureus in Positive Blood Cultures

T. Bhowmick; Stanley Mirrett; L B Reller; Connie S. Price; Chao Qi; Melvin P. Weinstein; Thomas J. Kirn

ABSTRACT Staphylococci are a frequent cause of bloodstream infections (BSIs). Appropriate antibiotic treatment for BSIs may be delayed because conventional laboratory testing methods take 48 to 72 h to identify and characterize isolates from positive blood cultures. We evaluated a novel assay based on bacteriophage amplification that identifies Staphylococcus aureus and differentiates between methicillin-susceptible and methicillin-resistant S. aureus (MSSA and MRSA, respectively) in samples taken directly from signal-positive Bactec blood culture bottles within 24 h of positive signal, with results available within 5 h. The performance of the MicroPhage KeyPath MRSA/MSSA blood culture test was compared to conventional identification and susceptibility testing methods. At four sites, we collectively tested a total of 1,165 specimens, of which 1,116 were included in our analysis. Compared to standard methods, the KeyPath MRSA/MSSA blood culture test demonstrated a sensitivity, specificity, positive predictive value, and negative predictive value of 91.8%, 98.3%, 96.3%, and 96.1%, respectively, for correctly identifying S. aureus. Of those correctly identified as S. aureus (n = 334), 99.1% were correctly categorized as either MSSA or MRSA. Analysis of a subset of the data revealed that the KeyPath MRSA/MSSA blood culture test delivered results a median of 30 h sooner than conventional methods (a median of 46.9 h versus a median of 16.9 h). Although the sensitivity of the test in detecting S. aureus-positive samples is not high, its accuracy in determining methicillin resistance and susceptibility among positives is very high. These characteristics may enable earlier implementation of appropriate antibiotic treatment for many S. aureus BSI patients.


Journal of Clinical Microbiology | 2004

Controlled Clinical Comparison of the BacT/ALERT FN and the Standard Anaerobic SN Blood Culture Medium

Stanley Mirrett; Cathy A. Petti; Christopher W. Woods; R. Magadia; Melvin P. Weinstein; L B Reller

ABSTRACT To determine the optimal anaerobic companion bottle to pair with the BacT/ALERT (bioMérieux, Durham, N.C.) nonvented aerobic FA (FA) medium for recovery of pathogenic microorganisms from adult patients with bacteremia and fungemia, we compared the BacT/ALERT FN (FN) anaerobic bottle with the standard BacT/ALERT SN (SN) anaerobic bottle. Each bottle, FA, FN, and SN, was filled with 8 to 12 ml of blood. Of 11,498 blood culture sets received in the clinical microbiology laboratories at two university medical centers, 7,945 sets had all three bottles filled adequately and 8,569 had both anaerobic bottles filled adequately. Of 686 clinically important (based on previously published criteria) isolates detected in one or both adequately filled anaerobic bottles, more staphylococci (P < 0.001), including Staphylococcus aureus (P < 0.001); members of the family Enterobacteriaceae (P < 0.001); and all microorganisms combined (P < 0.001) were detected in FN bottles. In contrast, more Pseudomonas aeruginosa isolates (P < 0.01) and yeasts (P < 0.001) were detected in SN bottles. More Bacteroides fragilis group bacteremias were detected only in the FN (six) than in the SN (one) anaerobic bottle (P = not significant). Overall, the mean time to detection was shorter with FN (16.8 h) than with SN (18.2 h). This difference in time to detection was greatest for the B. fragilis group: FN, 28 h, versus SN, 60.0 h. Many of the facultative microorganisms recovered in either FN or SN were also found in the companion FA. When microorganisms found in the companion FA bottle were omitted from the analysis, significantly more staphylococci (P < 0.001), including S. aureus (P < 0.001), and Enterobacteriaceae (P < 0.005) still were detected in FN bottles, whereas there were no significant differences for P. aeruginosa and yeasts, which were found as expected in FA bottles. We conclude that the companion anaerobic FN bottle detects more microorganisms than does the anaerobic SN bottle when used in conjunction with the nonvented aerobic FA bottle in the BacT/ALERT blood culture system.


European Journal of Clinical Microbiology & Infectious Diseases | 2008

Leptotrichia endocarditis: Report of two cases from the International Collaboration on Endocarditis (ICE) database and review of previous cases

Lauren B. Caram; J. P. Linefsky; Kerry Read; David R. Murdoch; Tahaniyat Lalani; Christopher W. Woods; L B Reller; Souha S. Kanj; M.M. Premru; Suzanne Ryan; Mashael Al-Hegelan; Pierre Yves Donnio; C. Orezzi; Marcelo Goulart Paiva; Christophe Tribouilloy; Richard Watkin; Owen C. Harris; Damon P. Eisen; G. R. Corey; C. H. Cabell; Cathy A. Petti

Leptotrichia species typically colonize the oral cavity and genitourinary tract. We report the first two cases of endocarditis secondary to L. goodfellowii sp. nov. Both cases were identified using 16S rRNA gene sequencing. Review of the English literature revealed only two other cases of Leptotrichia sp. endocarditis.


European Journal of Clinical Microbiology & Infectious Diseases | 1993

Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine.

Arthur L. Barry; Michael A. Pfaller; Peter C. Fuchs; F C Tenover; L B Reller; Stephen D. Allen; Dwight J. Hardy; E. H. Gerlach

Studies with fosfomycin tromethamine disks containing 200 µg of fosfomycin and 50 µg of glucose-6-phosphate confirmed the following zone diameter criteria for the NCCLS method: ≤12 mm for resistant (MIC≥256 µg/ml), 13–15 mm for intermediate (MIC 128 µg/ml) and ≥16 mm for susceptible (MIC≤64 µg/ml). Additional studies defined acceptable MIC and zone diameter ranges for the following quality control strains:Escherichia coli ATCC 25922, MIC 0.5 to 4.0 µg/ml, zone diameter 23 to 29 mm;Staphylococcus aureus ATCC 25923, zone diameter 26 to 32 mm;Pseudomonas aeruginosa ATCC 27813, MIC 2.0 to 8.0 µg/ml; andEnterococcus faecalis, ATCC 29212, MIC 16 to 64 µg/ml.


European Journal of Clinical Microbiology & Infectious Diseases | 1994

Interpretive criteria and quality control for antimicrobial susceptibility tests of levofloxacin

Arthur L. Barry; Peter C. Fuchs; F C Tenover; Stephen D. Allen; Dwight J. Hardy; James H. Jorgensen; J. McLaughlin; L B Reller

To confirm preliminary interpretive breakpoints for prototype 5 µg levofloxacin disks, 490 strains were tested in vitro using commercially manufactured disks. For in vitro susceptibility testing, 5 µg levofloxacin disks can be used with interpretive criteria of ≤ 12 mm for resistant (MIC ≥ 8.0 µg/ml) and ≥ 16 mm for susceptible (MIC ≤ 2.0 µg/ml). Proposed quality control limits for tests of levofloxacin are as follows:Escherichia coli ATCC 25922, zones 29–37 mm or MIC 0.008–0.03 µg/ml;Pseudomonas aeruginosa ATCC 27853, zones 19–26 mm or MIC 0.5–2.0 µg/ml;Staphylococcus aureus ATCC 25923, zones 24–31 mm;Staphylococcus aureus ATCC 29213, MIC 0.06–0.25 µg/ml andEnterococcus faecalis ATCC 29212, MIC 0.25–2.0 µg/ml.


Journal of Clinical Microbiology | 1994

Comparison of commercial kits for detection of cryptococcal antigen.

D. C. Tanner; Melvin P. Weinstein; B. Fedorciw; K. L. Joho; J. J. Thorpe; L B Reller


Journal of Clinical Microbiology | 1995

Controlled evaluation of BacT/Alert standard aerobic and FAN aerobic blood culture bottles for detection of bacteremia and fungemia

Melvin P. Weinstein; Stanley Mirrett; Larry G. Reimer; Michael L. Wilson; S. Smith-Elekes; C. R. Chuard; K. L. Joho; L B Reller


Journal of Clinical Microbiology | 1982

Controlled evaluation of the volume of blood cultured in detection of bacteremia and fungemia.

J H Tenney; L B Reller; Stanley Mirrett; W L Wang; Melvin P. Weinstein


Journal of Clinical Microbiology | 1994

Development of a standardized screening method for detection of vancomycin-resistant enterococci.

Jana M. Swenson; Nancye C. Clark; Mary Jane Ferraro; Daniel F. Sahm; G Doern; M A Pfaller; L B Reller; Melvin P. Weinstein; R J Zabransky; Fred C. Tenover

Collaboration


Dive into the L B Reller's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

F C Tenover

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

James H. Jorgensen

University of Texas Health Science Center at San Antonio

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge